Acute Intermittent Porphyria Market Latest Trends, Innovations, Analysis and Forecasts to 2027

The Acute Intermittent Porphyria Market report explores the size status and forecast 2022 market which transparent and clear picture of the current and future conditions of the market along with germane information regarding the market.

Logo

Pune, India -- (SBWire) -- 11/27/2017 --The Acute Intermittent Porphyria Market report has been thought of microscopically and the researchers have further infiltrated into industrial and production chain of the concerned market. This is also expected to help in broadcasting accurate statistics and data on multiple aspects concerning to the Global Acute Intermittent Porphyria Industry size status and forecast 2022.

The Global Acute Intermittent Porphyria Market is expected to grow at a CAGR of 5.6 % during the forecast period 2017-2023.

Acute intermittent porphyria (AIP) is a genetic metabolic disorder. It affects the production of heme, the oxygen-binding prosthetic group of hemoglobin. Generally, it is characterized by a deficiency of the enzyme porphobilinogen deaminase.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4713 .

The major causes of acute intermittent porphyria are abnormal urinary color, anorexia, insomnia, myalgia, and urinary retention. In some cases, AIP develops liver cancer (hepatocellular carcinoma), and some develop kidney failure. Other symptoms include gastrointestinal issues, urinary tract issues, neurological issues, psychiatric issues.

The acute intermittent porphyria market growth is majorly attributed to the increasing prevalence of the metabolic disorders, gastrointestinal issues, urinary tract issues, and healthcare insurance coverage. Moreover, increasing geriatric population will drive the market growth.

According to the Economic and Social Commission for Asia and the Pacific (ESCAP), in 2016, approximately 12.4% of the population in the region was over 60 years. According to Asian Development Bank, it was estimated that by 2050, 15% of total Malaysian population will be over 65 year old and in China, the elderly population will reach over 300 million by 2050. Thus, the increasing geriatric population in Asia is likely to help the growth of the market over the forecast period.

According to the WHO estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.

According to the American Liver Foundation, there is an increasing the prevalence of liver disease in the U.S. from then last few years. It further stated that at least 30 million people have some form of liver disease.

However, availability of expensive treatment and poor reimbursement policies in the developing regions of the world are some of the factors, which may hamper the market growth during the forecast period.

Order a Copy @ https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=4713 .

There are some of the prominent players profiled in MRFR Analysis and are competing in the Global Acute Intermittent Porphyria Market as Dahaner (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Siemens AG (U.S.), ARKRAY, Inc. (Japan), Sysmex Corporation (Japan), ACON Laboratories, Inc. (U.S.).

The global acute intermittent porphyria market is segmented on the basis by diagnosis, by treatment, and by end user.

On the basis of diagnosis, it is segmented into blood test, urine test, serum test, DNA test, and others.

On the basis of treatment, it is segmented into gonadotropin-releasing hormone analogues, prophylactic hematin infusions, and others.

On the basis of end user, it is segmented into hospitals & clinics, research centers, and others.

Major TOC of Acute Intermittent Porphyria Market:

1 INTRODUCTION

1.1 DEFINITION

1.2 SCOPE OF STUDY

1.2.1 RESEARCH OBJECTIVE

1.2.2 ASSUMPTIONS & LIMITATIONS

1.2.2.1 ASSUMPTIONS

1.2.2.2 LIMITATIONS

1.3 MARKET STRUCTURE:

2 RESEARCH METHODOLOGY

2.1 RESEARCH PROCESS:

2.2 PRIMARY RESEARCH

2.3 SECONDARY RESEARCH:

3 MARKET DYNAMICS

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 MACROECONOMIC INDICATORS

Inquire more @ https://www.marketresearchfuture.com/enquiry/4713 .

About Market Research Future
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Media Relations Contact

Akash Anand
08411985042
https://www.marketresearchfuture.com/reports/acute-intermittent-porphyria-market-4713

View this press release online at: http://rwire.com/895340